FTC Urged To Investigate AbbVie’s IP Strategy On Humira
US Representatives Suggest Biosimilar Adalimumab Competition Delayed From 2017 To 2023
• By David Wallace
The FTC has been asked to investigate AbbVie over delays to Humira biosimilars • Source: Alamy 
